- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07840521
Investigating Near-Threshold Perception During Ultrasonic Deep Brain Stimulation
This research is studying changes in awareness and metabolism in the brain that may take place in various brain regions stimulated with ultrasound (low-intensity focused ultrasound pulsation or LIFUP) while undergoing magnetic resonance imaging (MRI)-based brain measurements.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This study examines the effects of low-intensity focused ultrasound pulsation (LIFUP) on conscious perception and brain physiology in healthy adults using functional Magnetic resonance imaging (MRI), magnetic resonance spectroscopy, or multimodal glymphatic MRI. Participants are assigned by the study team to one of three arms, each involving up to five visits targeting different prespecified brain regions. Participants perform a visual perception task during imaging, with measurements obtained before, during, and after LIFUP. After completing their initially assigned arm, participants may re-enroll in another arm or for a repeat visit following re-screening and new informed consent.
Randomization applies to the order of procedures within each arm, not to assignment of participants among the three arms. The order in which the five brain regions are targeted will be randomized across participants in all three experimental arms
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Amy McKinney
- Número de teléfono: 734-647-8129
- Correo electrónico: adrongo@med.umich.edu
Ubicaciones de estudio
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan
-
Contacto:
- Amy McKinney
- Número de teléfono: 734-647-8129
- Correo electrónico: adrongo@med.umich.edu
-
Investigador principal:
- Zirui Huang
-
Investigador principal:
- Anthony Hudetz
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Participants must be right-handed, English-speaking, and capable of providing written informed consent.
- Participants must have normal or corrected-to-normal vision while wearing contact lenses,
- Participants must have a body mass index of less than 30
- Participants must not be taking medications for any neurological, psychological, or psychiatric condition.
Exclusion Criteria:
- Participants will be excluded if they have any contraindication to MRI scanning, including possible pregnancy, current breastfeeding BMI greater than 30, metallic substances or implants in the body, claustrophobia, anxiety that would prevent MRI scanning, Participants with tattoos in the head or neck region will also be excluded, while tattoos in other locations will be evaluated by the investigators to determine whether they pose a safety concern.
- cardiopulmonary disease, or an intracranial structural abnormality identified on T1-weighted MRI.
- Women of childbearing potential will be required to complete a study-funded pregnancy test before participation and must have a negative result.
- vision that is not 20/20 or corrected to 20/20 with contact lenses, a history of significant head injury involving loss of consciousness
- a learning disability or other developmental disorder
- any sensory or motor impairment, activity, condition, or circumstance that, in the judgment of the study coordinator or Principal Investigators, would prevent satisfactory completion of the study protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: LIFUP-fMRI
Participants assigned to the fMRI arm will complete five visits, with a different brain region targeted at each visit. Each visit will include seven consecutive 10-minute scanning periods: one pre-LIFUP baseline fMRI scan, five fMRI scans conducted during LIFUP using five predefined combinations of duty cycle and pulse repetition frequency, and one post-LIFUP baseline fMRI scan. The five stimulation parameter combinations will be labeled Combination 1 through Combination 5. The order of the five parameter combinations will be randomized within each visit. The total planned scanning time for these seven periods is approximately 70 minutes, excluding structural imaging, participant positioning, transducer placement, safety checks, and other required study procedures. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. Whole-brain functional images will be acquired using a multiband gradient-echo echo-planar imaging sequence with the following parameters: 60 slices, repetition time (TR) = 800 ms, echo time (TE) = 30 ms, flip angle = 52°, multiband acceleration factor = 6, slice thickness = 2.4 mm, in-plane resolution = 2.4 × 2.4 mm, FOV = 216 × 216 mm, and image matrix = 90 × 90. MRI acquisition and associated study procedures will be completed within a scanning visit lasting no more than approximately 2 hours. |
|
Experimental: LIFUP-magnetic resonance spectroscopy (MRS)
Participants assigned to the MRS arm will also complete five visits, with a different brain region targeted at each visit. Each visit will include a pre-LIFUP baseline MRS acquisition, an excitatory LIFUP condition, a post-excitatory non-LIFUP MRS acquisition, an inhibitory LIFUP condition, and a post-inhibitory non-LIFUP MRS acquisition. Each MRS acquisition period will last approximately 13 minutes and will include approximately 5 minutes of glutamate plus glutamine measurement and 8 minutes of gamma-aminobutyric acid (GABA) measurement. The order of the excitatory and inhibitory LIFUP conditions will be randomized across participants. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. Single-voxel proton magnetic resonance spectroscopy will be performed. A nominal 15 × 15 × 10 mm spectroscopy voxel will be positioned at the prespecified brain target using the participant's anatomical MRI. Glutamate plus glutamine (Glx) will be measured using a short-echo-time spectroscopy sequence with an acquisition time of approximately 5 minutes. GABA will be measured using an edited spectroscopy sequence with an acquisition time of approximately 8 minutes. An unsuppressed water-reference scan will also be acquired for signal correction and metabolite quantification. Voxel placement, shimming, and other sequence parameters may be adjusted slightly based on target anatomy, scanner requirements, and data quality while maintaining the planned procedures and approximate acquisition times. |
|
Experimental: LIFUP-Glymphatic MRI
Participants assigned to the glymphatic MRI arm will complete up to five visits, with a different prespecified brain region targeted at each visit. Tissue-to-fluid water exchange, velocity spectrum imaging, and cerebral perfusion using arterial spin labeling will be assessed before, during, and after LIFUP. The planned imaging periods total approximately 1.5 hours per visit, excluding participant positioning, structural imaging, transducer placement, safety checks, and other required study procedures. |
LIFUP will be used to stimulate specific brain regions and assess their causal involvement in the control of conscious state and contents. The study team will collect three separate measurements related to glymphatic function. (i) Multi-delay pseudo-continuous arterial spin labeling (PCASL) MRI with a 3D stack of spirals (SOS) gradient and spin echo (GRASE) read-out. Labeling durations from 500 to 2000 ms, TR = 6 sec., background suppression. FOV = 24 cm with 3x3x5 mm resolution. (ii) Tissue-to-fluid Water exchange rate using T2 selective saturation labeling pulses using the same resolution parameters. (iii) Velocity Spectrum Imaging using velocity selective preparation pulses followed by spherical spiral projection imaging (FOV = 24 cm, velocity bandwidth = [-1, 1] cm/s, isotropic spatial resolution = 3.5 mm). |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Blood Oxygen Level Dependent (BOLD) response to visual stimuli
Periodo de tiempo: Approximately 70 minutes
|
Changes in task-evoked blood oxygen level-dependent responses to visual stimuli will be measured using functional MRI before, during, and after LIFUP across the five stimulation parameter conditions. |
Approximately 70 minutes
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Perceptual criterion (c) derived from the Signal Detection Theory (SDT)
Periodo de tiempo: Approximately 65-75 minutes
|
The perceptual response criterion, c, will be calculated from participants' recognition responses using Signal Detection Theory to quantify their tendency to report conscious recognition of a visual stimulus. For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no". |
Approximately 65-75 minutes
|
|
Perceptual sensitivity (d') derived from the Signal Detection Theory (SDT)
Periodo de tiempo: Approximately 75 minutes
|
Perceptual sensitivity, d', will be calculated from participants' visual discrimination responses using Signal Detection Theory to quantify their ability to distinguish intact object images from control stimuli. For each scanning session, the study team will calculate sensitivity (d') and criterion (c) using subjective reports of recognition as "yes" or "no". |
Approximately 75 minutes
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Zirui Huang, University of Michigan
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Manifestaciones neurológicas
- Enfermedades del Sistema Nervioso
- Desordenes mentales
- Manifestaciones neuroconductuales
- Trastornos neurocognitivos
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Trastornos de la conciencia
- Técnicas de investigación
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Tomografía
- Imágenes de diagnóstico
- Técnicas de química, analítica
- Análisis de espectro
- Imágenes de resonancia magnética
- Espectroscopía de resonancia magnética
Otros números de identificación del estudio
- HUM00251769
- 2R01GM103894 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .